Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis

Orladeyo (berotralstat) - BioCryst Pharmaceuticals

https://events.rdmobile.com/Lists/Details/3220770

Mark Davis-Lorton MD FAAAAI 1; Raffi Tachdjian MD MPH FAAAAI 2; Tracy Yee 3; Francois Laliberte 4; Ramya Ramasubramanian PhD 4; Sandra Nestler-Parr 3; Patrick Gillard 5; William Lumry MD FAAAAI 6

Feb 10, 2026